Annovis Bio Inc. – Filings and Transcripts

NYSE: ANVS
Share price (8/17/26): $1.74
Market cap (8/17/26): $74.1 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

Highbridge Capital Management LLC

Empery Asset Management, LP

Hoffman Michael B

Hoffman Michael B

News Filter

Pivotal Phase 3 Alzheimer’s Disease (AD) Trial Is Fully Enrolled With a Total Number of 850 Patients, Exceeding Original Projections

Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Shareholder Vote Results, Financial Statements or Exhibits

Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

Phase 3 AD Trial: 85% of Patients Enrolled; Full Enrollment on Track in Summer 2026

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Scanned paper annual report submission